Brainstorm Cell Therapeutics Inc.
BCLI- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001137883
No open-market purchases or sales by Brainstorm Cell Therapeutics Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding BCLI, Q2 2026
No superinvestor reported holding BCLI at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Brainstorm Cell Therapeutics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2024 (view filing)8:00 AM ET | Sep 30-Oct 1 | 2 days | Lebovits ChaimPresident & CEO | PPurchase | +23.8K | $0.4744 | +$11.3K | +41.7%81.0K after | 2 lots |
| Jul 31, 2024 (view filing)4:07 PM ET | May 10-13 | 82 days | Lebovits ChaimPresident & CEO | PPurchase | +40.0K | $0.4716 | +$18.9K | +3.8%1.10M after | Amended3 lots |
| Jul 31, 2024 (view filing)4:07 PM ET | May 7 | 85 days | Lebovits ChaimPresident & CEO | PPurchase | +66.3K | $0.3743 | +$24.8K | +6.7%1.06M after | Amended |
| Jul 31, 2024 (view filing)4:06 PM ET | May 6 | 86 days | Lebovits ChaimPresident & CEO | PPurchase | +135.0K | $0.3753 | +$50.7K | +15.7%993.6K after | Amended |
| Jul 31, 2024 (view filing) | May 28 | 64 days | Lebovits ChaimPresident & CEO | PPurchase | +15.0K | $0.52 | +$7.80K | +1.3%1.16M after | Amended |
| Jul 31, 2024 (view filing) | May 21-22 | 71 days | Lebovits ChaimPresident & CEO | PPurchase | +50.0K | $0.61 | +$30.5K | +4.5%1.15M after | Amended2 lots |
| Jul 31, 2024 (view filing) | Apr 19 | 103 days | Lebovits ChaimPresident & CEO | PPurchase | +15.0K | $0.52 | +$7.80K | +1.8%858.6K after | Amended |
| Jul 31, 2024 (view filing) | Apr 17-18 | 105 days | Lebovits ChaimPresident & CEO | PPurchase | +245.1K | $0.5406 | +$132.5K | +40.9%843.6K after | Amended2 lots |
| Jul 24, 2024 (view filing)4:05 PM ET | Jul 19 | 5 daysLate | Dagher Ibrahim B.Chief Medical Officer | SSale | −63.0K | $0.3503 | −$22.1K | −100.0%0 after | |
| Sep 5, 2023 (view filing) | Sep 1 | 4 days | Lindborg StacyCo-Chief Executive Officer | PPurchase | +11.5K | $1.77 | +$20.4K | +6.8%181.5K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Brainstorm Cell Therapeutics Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding BCLI in 13F filings for Q2 2026.